- 全部删除
- 您的购物车当前为空
Anti-diabetic drugs of the thiazolidinedione (TZD) structural class as well as α-lipoic acid activate peroxisome proliferator-activated receptor γ (PPARγ), a nuclear transcription factor that controls glucose metabolism and lipid homeostasis. CAY10506 is a hybrid lipoic acid-TZD derivative that transactivates human PPARγ with an EC50 value of 10 μM.
Anti-diabetic drugs of the thiazolidinedione (TZD) structural class as well as α-lipoic acid activate peroxisome proliferator-activated receptor γ (PPARγ), a nuclear transcription factor that controls glucose metabolism and lipid homeostasis. CAY10506 is a hybrid lipoic acid-TZD derivative that transactivates human PPARγ with an EC50 value of 10 μM.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | ¥ 5,960 | 35日内发货 |
产品描述 | Anti-diabetic drugs of the thiazolidinedione (TZD) structural class as well as α-lipoic acid activate peroxisome proliferator-activated receptor γ (PPARγ), a nuclear transcription factor that controls glucose metabolism and lipid homeostasis. CAY10506 is a hybrid lipoic acid-TZD derivative that transactivates human PPARγ with an EC50 value of 10 μM. |
别名 | CAY10506 |
分子量 | 454.63 |
分子式 | C20H26N2O4S3 |
CAS No. | 292615-75-9 |
密度 | 1.305 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度信息 | Ethanol: 3 mg/mL DMF: 5 mg/mL DMSO:PBS(pH 7.2) (1:5): 0.15 mg/mL DMSO: 5 mg/mL |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容